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Abstract: Cholangiocarcinoma is a disease with a poor prognosis and increasing incidence and hence
there is a pressing unmet clinical need for new adjuvant treatments. Protein kinase CK2 (previously
casein kinase II) is a ubiquitously expressed protein kinase that is up-regulated in multiple cancer
cell types. The inhibition of CK2 activity using CX-4945 (Silmitasertib) has been proposed as a novel
treatment in multiple disease settings including cholangiocarcinoma. Here, we show that CX-4945
inhibited the proliferation of cholangiocarcinoma cell lines in vitro. Moreover, CX-4945 treatment
induced the formation of cytosolic vacuoles in cholangiocarcinoma cell lines and other cancer cell lines.
The vacuoles contained extracellular fluid and had neutral pH, features characteristic of methuosis.
In contrast, simultaneous knockdown of both the α and α′ catalytic subunits of protein kinase CK2
using small interfering RNA (siRNA) had little or no effect on the proliferation of cholangiocarcinoma
cell lines and failed to induce the vacuole formation. Surprisingly, low doses of CX-4945 increased the
invasive properties of cholangiocarcinoma cells due to an upregulation of matrix metallopeptidase 7
(MMP-7), while the knockdown of CK2 inhibited cell invasion. Our data suggest that CX-4945 inhibits
cell proliferation and induces cell death via CK2-independent pathways. Moreover, the increase
in cell invasion brought about by CX-4945 treatment suggests that this drug might increase tumor
invasion in clinical settings.
Keywords: protein kinase CK2; CX-4945; cholangiocarcinoma; non-canonical cell death; methuosis
1. Introduction
Cholangiocarcinoma (CCA) is a cancer of bile duct epithelia thought to arise as a result of chronic
inflammation of the liver and bile ducts. The incidence of CCA has increased gradually worldwide
during the last three decades [1–4]. The incidence of this disease is highest in Southeast Asia [5]
Cancers 2018, 10, 283; doi:10.3390/cancers10090283 www.mdpi.com/journal/cancers
Cancers 2018, 10, 283 2 of 22
particularly in the northeastern provinces of Thailand due to persistent liver fluke infection [6,7].
Although, surgery is considered the best treatment option, most patients are not suitable for surgery
on presentation [8,9]. Moreover, approximately 70% of intrahepatic cholangiocarcinoma patients have
a recurrence of disease post-surgery [10]. Adjuvant capecitabine treatment is effective post-surgery
but median survival is only around four years [11]. Non-resectable disease can be treated using
radiation and gemcitabine and cisplatin as first-line chemotherapy. However, median overall survival
remains very poor at only around 12 months [12]. Therefore, there is an urgent unmet clinical need
for new adjuvant therapies that could prevent recurrence as well as for new and effective second line
drug treatments.
Protein kinase CK2 (previously casein kinase II), a ubiquitously expressed serine/threonine kinase,
forms a tetrameric holoenzyme composed of two catalytic subunits, which are alpha (α) or alpha′ (α′),
or a combination of both, and two regulatory beta (β) subunits [13]. CK2 levels in many cancer types
are abnormally high [14]. CK2 promotes cell survival and was shown to suppress apoptosis in various
cancer types, such as HeLa and the gastric cancer cell line SGC-7901, where CK2 phosphorylated
apoptosis repressor with caspase recruitment domain (ARC) [15]. In addition, CK2 promoted malignant
peripheral nerve sheath tumors (MPNST) cell survival by stabilizing β-catenin [16]. Downregulation
of CK2 with short hairpin RNA (shRNA) or with CX-4945 also known as Silmitasertib, a CK2 inhibitor,
caused MPNST cells to arrest in the G2/M phase and undergo apoptosis [16]. Downregulation of CK2
with small interfering (siRNA) or by using CX-4945 induced apoptosis in non-small cell lung cancer
cell lines by downregulation of Akt and its downstream signals [17]. Similarly, apoptosis was observed
in acute myeloid leukemia cells by a p53-dependent mechanism after CK2 knockdown or CX-4945
application [18]. Furthermore, stable knockdown of CK2 sensitized HEp-2 laryngeal carcinoma cells to
cisplatin-induced apoptosis [19].
CK2 has been proposed as a drug target for many cancers. Downregulation of protein kinase
CK2 induced the senescent phenotype in human diploid fibroblast IMR-90 cells [20], and decreased
androgen receptor nuclear translocation, which led to a reduced expression of genes required for
prostate cancer cell proliferation [21]. CX-4945 has also been shown to decrease the survival of many
cancer cell types including bladder [22], hematological [23,24], prostate [25], and breast cancer cells [26].
CX-4945 up to 10 µM showed an inhibition on Akt phosphorylation in prostate cancer, PC3 cells,
and [27] non-small cell lung cancer cells, H1299, Calu-1, and H358 [17]. It also induced cell cycle
arrest and apoptosis in the aforementioned prostate and non-small cell lung cancer cell lines [17,27].
An in vivo study showed that CX-4045 up to 75 mg/kg was safe in mice and inhibited PC3 tumor
xenograft growth [27]. In primary human mucin- and mixed-intrahepatic CCA, CX-4945 up to 50 µM
significantly decreased the viability of primary human cell cultures and induced apoptosis at 10 µM,
whereas Cytokeratin 19 (CK19)-positive cells required a higher dose at 30 µM [28]. CX-4945 increased
the number of γ-H2AX positive cells that are a marker for DNA double-strand breaks [28]. However,
inhibition of DNA-PK (DNA-dependent protein kinase), previously reported as downstream of CK2
in glioblastoma cells [29], unexpectedly reduced γ-H2AX positive cells in primary human intrahepatic
CCA cells [28]. This suggested that DNA-PK and also possibly CK2 in the setting of CCA acted as
negative modulators of DNA double strand break repair, which is opposite from the mechanism
reported in glioblastoma [29] and leukemia [30].
Interestingly, CX-4945 at 1 and 10 µM was recently shown to have off-target effects. The inhibition
of Cdc2-like kinases (Clks) from these doses of CX-4945 resulted in a suppression of phosphorylation
of serine/arginine (S/R) rich proteins in mammalian cells [31]. In addition, CX-4945 has been shown
to affect alternative splicing of a wide range of genes, including CK2 itself, in a CK2-independent
manner in the HEK293T cell line [31].
Although apoptosis is the most widely recognized form of physiological programmed cell death,
several non-apoptotic cell death mechanisms have been reported to date. One distinct characteristic of
many non-apoptotic cell death mechanisms is the formation of cytoplasmic vacuoles. The origin of
the cytoplasmic vacuoles in different non-canonical cell death mechanisms is different yet not unique.
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One relatively well known non-apoptotic cell death is autophagy. Autophagy forms autophagosomes
that are double-membrane vacuoles [32–34]. In contrast, methuosis, a recently described cell death
mechanism, utilizes single-membrane vacuoles from macropinocytosis [35–37]. A few other types
of non-apoptotic cell death mechanisms share a similar origin for the formation of cytoplasmic
vacuoles. Oncosis, paraptosis, and necroptosis form vacuoles from endoplasmic reticulum (ER)
and mitochondria [35,38–42].
Methuosis is derived from the Greek methuo (to drink to intoxication) because the hallmark of
this form of cell death is the formation of large fluid-filled vacuoles derived from macropinosomes.
The demise of the cell resembles many forms of necrosis, with loss of metabolic capacity and plasma
membrane integrity. Moreover, cell shrinkage and nuclear fragmentation associated with apoptosis
are not observed [35]. Methuosis was initially defined in glioblastoma cells after ectopic expression
of activated Ras [36,37], but recent reports have described small molecules, including indole-based
chalcone 3-(2-methyl-1H indol-3-yl)-1-(4-pyridinyl)-2-propen-1-one (MIPP) and MOMIPP, which has
a 5-methoxy group added to the indole ring of MIPP, that can induce the features of methuosis [37,43].
Herein, we report for the first time that CX-4945 at low doses stimulated CCA cell invasion due to
an upregulation of matrix metallopeptidase 7 (MMP-7) and matrix metallopeptidase 9 (MMP-9). Also,
CX-4945 induced cytosolic vacuolization, which met the criteria of methuosis, via a CK2-independent
mechanism in a dose- and time-dependent manner.
2. Results
2.1. CX-4945 Inhibits CK2 Activity at High Dose
To investigate the effects of CX-4945 on CCA cells, we treated three CCA cell lines with increasing
amounts of this drug. CX-4945 reduced CK2 activity in a dose-dependent manner 4 h post-treatment
as determined using Western blotting with an antibody that recognizes phosphorylated CK2 sites in
multiple proteins (Figure 1a). The CCA cell lines all showed a reduction in multiple phospho-CK2
substrates with apparent molecular masses of approximately 200, 180, 100, 60, 37, 35, and 33 kDa as
indicated by arrows in the Figure (Figure 1a).
2.2. CX-4945 Treatment Inhibits CCA Cell Proliferation
To determine the effects of CX-4945 on CCA cell proliferation we treated the three cell lines
described above and examined the effect on cell number and 5-bromo-2′-deoxyuridine (BrdU)
incorporation. After 5 days of treatment, CX-4945 at 5 µM or higher doses reduced CCA cell number
in all of the cell lines (Figure 1b). CX-4945 at 5 µM reduced CCA cell number to approximately 50% of
the vehicle control in HuCCA-1, KKU-M213 cells and in CCLP-1 approximately to 70% as compared to
vehicle control group at 5-days post-treatment. CCA cells treated with 10 and 15 µM CX-4945 did not
increase in number over 5 days in culture (Figure 1b), and higher doses of CX-4945 (25 and 50 µM)
decreased cell number significantly at 5 days after treatment (Figure 1b). To determine whether the
reduction in cell number is accompanied by reduced cell proliferation, we examined the effects of
CX-4945 on 5-bromo-2′-deoxyuridine (BrdU) incorporation. CX-4945 at 25 and 50 µM inhibited BrdU
incorporation on all CCA cell lines by approximately 50% and 25%, respectively, at 24 h post-treatment
(Figure 1c). A slightly lower inhibition was observed on CCLP-1 cells (Figure 1c).
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Figure 1. The effects of CX-4945 on cholangiocarcinoma (CCA) cell lines. (a) CX-4945 (Silmitasertib) 
inhibited CK2 (previously casein kinase II) activity in a dose-dependent manner. Arrows indicate CK2 
phospho-substrates that decrease in intensity with CX-4945 treatment. (b) CX-4945 at 5 µM and higher 
doses reduced CCA cell number in three CCA cell lines as determined using MTT assays. (c) CX-4945 
at 25 and 50 µM inhibited CCA cell lines proliferation in a 5-bromo-2′-deoxyuridine (BrdU) 
incorporation assay 24 h post-treatment. (d) CX-4945 exerted a biphasic effect on cell invasion through 
Matrigel. CX-4945 at 5 µM or lower doses induced invasion by HuCCA-1 cells and KKU-M213 cells 
while CX-4945 at 10 µM inhibited CCA cell invasion through Matrigel. (e) Twenty-four hours’ post-
treatment of CX-4945 at low doses upregulated matrix metallopeptidase 7 (MMP-7) level while 10 µM 
CX-4945 downregulated MMP-7 level. MMP-2 and MMP-9 levels were not altered. (f) Quantitative 
data of protein level changes post treatment of CX-4945 in panel (e). VC; vehicle control, *; p < 0.05, **; 
p < 0.01, ***; p < 0.001. All experiments were performed in triplicate and with at least at three biological 
replicates. Graphs were plotted as mean ± SEM. 
  
Figure 1. The effects of CX-4945 on cholangiocarcinoma (CCA) cell lines. (a) CX-4945 (Silmitasertib)
inhibited CK2 (previously casein kinase II) activity in a dose-dependent manner. Arrows indicate CK2
phospho-substrates that decrease in intensity with CX-4945 treatment. (b) CX-4945 at 5 µM and higher
doses reduced CCA cell number in three CCA cell lines as determined using MTT assays. (c) CX-4945 at
25 and 50 µM inhibited CCA cell lines proliferation in a 5-bromo-2′-deoxyuridine (BrdU) incorporation
assay 24 h post-treatment. (d) CX-4945 exerted a biphasic effect on cell invasion through Matrigel.
CX-4945 at 5 µM or lower doses induced invasion by HuCCA-1 cells and KKU-M213 cells while
CX-4945 at 10 µM inhibited CCA cell invasion through Matrigel. (e) Twenty-four hours’ post-treatment
of CX-4945 at low doses upregulated matrix metallopeptidase 7 (MMP-7) level while 10 µM CX-4945
downregulated MMP-7 level. MMP-2 and MMP-9 levels were not altered. (f) Quantitative data of
protein level changes post treatment of CX-4945 in panel (e). VC; vehicle control, *; p < 0.05, **; p < 0.01,
***; p < 0.001. All experiments were performed in triplicate and with at least at three biological replicates.
Graphs were plotted as mean ± SEM.
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2.3. CX-4945 Treatment Alters Cell Invasion
Protein kinase CK2 is known to be important in cell migration and cancer cell invasion. To determine
the effects of CX-4945 on CCA cell invasion we examined the ability of the cells to traverse a layer of
Matrigel in vitro. CX-4945 treatment showed biphasic effects on CCA cell invasion though Matrigel.
CX-4945 at 10 µM significantly inhibited cell invasion through Matrigel in the three CCA cell lines
tested (Figure 1d). In contrast, lower concentrations of CX-4945 stimulated invasion in all CCA cell
lines tested (Figure 1d). The increase in cell invasion at low CX-4945 doses was not due to an increase in
cell number as the assays were performed at the same time point (24 h post-treatment) that was shown
by BrdU assay to have equivalent proliferation rates between the control and CX-4945 treated groups
(1 and 5 µM) (Figure 1c). In addition, MTT assay at a later time point (48 h post-treatment) also showed
no difference in cell number between these groups (Figure 1b). The increase in cell invasion was at
least in part due to an increase in MMP-9, MMP-7, and matrix metallopeptidase 2 (MMP-2) levels in
CCLP-1, and an increase in MMP-7 levels in HuCCA-1 and KKU-M213 (Figure 1e,f). The decrease in
cell invasion at 10 µM of CX-4945 was at least in part due to a decrease in MMP-9 and MMP-7 levels
in HuCCA-1 and to MMP-7 levels in KKU-M213. In addition to a decrease in MMP levels, a smaller
invasion in the 10 µM CX-4945-treated group was also likely to be a consequence of the inhibition
of cell proliferation at this dose (Figure 1b,c). We conclude that at lower doses, CX-4945 treatment
increased the ability of CCA cells to invade Matrigel, while higher doses inhibited this ability.
2.4. CX-4945 Treatment Induces Intensive Vacuolization
Prominent vacuoles were observed as soon as 1 h after CX-4945 treatment in all CCA cell lines
tested (Figure 2a–c). The number of the vacuoles at 24 h post-treatment increased in a dose-dependent
manner in CX-4945 treated HuCCA-1, CCLP-1, and KKU-M213 cells (Figure 2d,h,l). The number of
vacuoles also increased in a time-dependent manner until 4 h post-treatment in HuCCA-1 (Figure 2e)
or 2 h after treatment in CCLP-1 and KKU-M213 (Figure 2i,m) before declining at later time points.
This reduction in vacuole number might be due to the fusion of small vacuoles into larger ones.
In keeping with this view, the size of the vacuoles increased in a dose- and time-dependent manner
(Figure 2f,g,j,k,n,o). The vacuoles filled most of the cytoplasm at 24 h after treatment in cells treated
with 50 µM CX-4945 (Figure 2a–c). To determine whether vacuole formation is limited to CCA cells,
we next treated a variety of other CCA cells and non-CAA cells with CX-4945. CX-4945 treatment
induced vacuole formation in all of the additional CCA cell lines tested (Figure 3a). Furthermore,
50 µM CX-4945 treatment at 4 h also induced intensive vacuolization in immortalized cholangiocytes
(MMNK-1 and AKN-1 cells), as well as breast cancer cell lines (MDA-MB-231 and T47D), prostate
cancer cell line DU145, and human embryonic kidney cells (HEK293T). However, one prostate cancer
cell line (PC3) did not form vacuoles at all under the conditions tested, and one breast cancer cell line
(MCF-7) formed only a few vacuoles in some cells (Figure 3a). Interestingly, although the cell area of
the cell lines that form vacuoles did not decrease (Figure 3b), PC3 cell area decreased approximately
50% as compared to the vehicle control group (Figure 3b).
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Figure 2. CX-4945 induced vacuolization. (a–c) CX-4945 induced intensive vacuolization in CCA cells. 
CX-4945 induced vacuolization in CCA cell lines in a dose- (d,f,h,j,l,n) and time- (e,g,i,k,m,o) 
dependent manner. VC; vehicle control, *; p < 0.05, **; p < 0.01, ***; p < 0.001, #; significantly different 
from all other groups at p < 0.001. All experiments were performed with at least three biological 
replicates. Graphs were plotted as mean ± SEM. 
Figure 2. CX-4945 induced vacuolization. (a–c) CX-4945 induced intensive vacuolization in CCA
cells. CX-4945 induced vacuolization in CCA cell lines in a dose- (d,f,h,j,l,n) and time- (e,g,i,k,m,o)
dependent manner. VC; vehicle control, *; p < 0.05, **; p < 0.01, ***; p < 0.001, #; significantly different
from all other groups at p < 0.001. All experiments were performed with at least three biological
replicates. Graphs were plotted as mean ± SEM.
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Figure 3. CX-4945 induced vacuolization in a wide range of cancer and immortalized cell lines. (a) 
CCA cells (HuCCA-1, CCLP-1, KKU-M213, KKU-M055, and KKU-100) and immortalized 
cholangiocytes (MMNK-1 and AKN-1), breast cancer cells (MDA-MB-231 and T48D), prostate cancer 
cells (DU145), and human embryonic kidney cells (HEK293T) form intensive cytoplasmic vacuoles at 
4 h after CX-4945 treatment. Breast cancer cells, MCF-7, formed only few vacuoles in small number of 
cells, while prostate cancer cell, PC3, did not form any vacuoles. (b) Cell area of cell lines that formed 
vacuoles did not altered, but PC3 cell area decreased to approximately 50% as compared to the vehicle 
control group. VC; vehicle control, ***; p < 0.001, NS; not significant. Pictures are representative of the 
results from three independent experiments. Graphs were plotted as mean ± SEM. 
2.5. CX-4945 Induces Caspase-3 Independent Non-Autophagic Cell Death in CCA Cells 
To determine whether vacuolization was accompanied by increased cell death, we treated CCA 
cells with CX-4945 and stained live cells with calcein and dead cells with propidium iodide. No 
significant increase in the number of dead cells was observed after 4 h of CX-4945 treatment (Figure 
4a,c,e), which was the time point where a decreased level of CK2 activity was observed with CX-4945 
treatment (Figure 1a). However, CX-4945 at 25 and 50 µM significantly induced cell death in HuCCA-
1 cells (Figure 4b) and KKU-M213 cells (Figure 4f) at 48 h post-treatment. Although there was no 
significant increase in the number of dead CCLP-1 cells following treatment with CX-4945, the total 
number of cells 48 h post-treatment was clearly reduced (Figure 4d, calcein panels). This was also 
seen in the other cell lines (Figure 4b,f). The percentage of dead cells was increased in a dose-
dependent manner from approximately 1–3% in the vehicle control group to 12% (CCLP-1) or 20% 
Figure 3. CX-4945 induced vacuolization in a wide range of cancer and immortalized cell lines. (a) CCA
cells (HuCCA-1, CCLP-1, KKU-M213, KKU-M055, and KKU-100) and immortalized cholangiocytes
(MMNK-1 and AKN-1), breast cancer cells (MDA-MB-231 and T48D), prostate cancer cells (DU145),
and human embryonic kidney cells (HEK293T) form intensive cytoplasmic vacuoles at 4 h after CX-4945
treatment. Breast cancer cells, MCF-7, formed only few vacuoles in small number of cells, while prostate
cancer cell, PC3, did not form any vacuoles. (b) Cell area of cell lines that formed vacuoles did not
altered, but PC3 cell area decreased to approximately 50% as compared to the vehicle control group.
VC; vehicle control, ***; p < 0.001, NS; not significant. Pictures are representative of the results from
three independent experiments. Graphs were plotted as mean ± SEM.
2.5. CX-4945 Induces Caspase-3 Independent Non-Autophagic Cell Death in CCA Cells
To determine whether vacuolization was accompanied by increased cell death, we treated
CCA cells with CX-4945 and stained live cells with calcein and dead cells with propidium iodide.
No significant increase in the number of dead cells was observed after 4 h of CX-4945 treatment
(Figure 4a,c,e), which was the time point where a decreased level of CK2 activity was observed with
CX-4945 treatment (Figure 1a). However, CX-4945 at 25 and 50 µM significantly induced cell death in
HuCCA-1 cells (Figure 4b) and KKU-M213 cells (Figure 4f) at 48 h post-treatment. Although there was
no significant increase in the number of dead CCLP-1 cells following treatment with CX-4945, the total
Cancers 2018, 10, 283 8 of 22
number of cells 48 h post-treatment was clearly reduced (Figure 4d, calcein panels). This was also seen
in the other cell lines (Figure 4b,f). The percentage of dead cells was increased in a dose-dependent
manner from approximately 1–3% in the vehicle control group to 12% (CCLP-1) or 20% (HuCCA-1
and KKU-M213) in 50 µM treated group (Figure 4g). Interestingly, the number of apoptotic cells
did not increase in these cells after treatment with CX-4945 at any concentration for 48 h (Figure 5a),
while cell death was detected at 48 h post-treatment. Etoposide treated KKU-M213 cells were used as
positive control for the cleaved caspase-3 apoptosis assay. Furthermore, the vacuoles that presented
after CX-4945 treatment do not appear to be autophagosomes since levels of the autophagosomal
marker LC3B-II decreased (Figure 5a) while the number and size of the vacuoles increased (Figure 2).
Although HuCCA-1 treated with 10 and 25 µM CX-4945 showed an increased level of LC3B-II, the cells
treated with 50 µM, which is the concentration where the highest number of vacuoles was observed,
showed a decreased level of LC3B-II. Moreover, a decreased level of LC3B-II was observed in both
CCLP-1 and KKU-M213 treated with CX-4945 (Figure 5a). To further examine the involvement of
LC3B-II in the vacuolization induced by CX-4945, a time-course treatment of 50 µM CX-4945 was
performed. The level of LC3B-II was elevated at early time points post-treatment in HuCCA-1 and
CCLP-1 cells, but it decreased significantly at 4 h post-treatment. A similar trend was observed in
KKU-M213 cells where the level of LC3B-II at earlier time points was higher than that at 4 h (Figure 5b,c).
We conclude that CX-4945 is likely to induce non-canonical cell death in these cell lines. However,
the LC3B-II protein might be involved in the initiation of vacuole formation.
2.6. CX-4945 Induced Methuosis in KKU-M213
All cell lines used in these studies, except PC3 cells which did not form vacuoles (Figure 3a),
showed no change in cell area (Figure 3b) and had no membrane blebbing (Figure 3a). Although
their cytoplasm was filled with vacuoles, the cell membrane was well-spread and cell shape was
normal as compared to the vehicle control group (Figure 3a). To further identify the cell death
mechanism induced by CX-4945 in CCA cell lines, the nucleus and ER of cells treated with CX-4945
were examined. First, nuclear staining with DAPI showed that the nucleus of cells treated with
25 µM CX-4945 for 24 h were still intact. No chromatin condensation or nuclear fragmentation was
observed (Figure 6a). Second, KKU-M213, which are cells that are most sensitive to CX-4945 in
terms of vacuole formation, were incubated for 72 h with CellLight® ER-GFP BacMam 2.0 (C10590,
Fisher Scientific, Hampton, NH, USA). This reagent transfected and expressed GFP-fused ER signal
sequence, calreticulin, and KDEL, in live cells, thereby labeled ER with GFP. The ER of KKU-M213
treated with CX-4945 covered a large part of cytoplasm but did not overlap with the vacuoles
(Figure 6b). Some large vacuoles reside near the nucleus and, therefore, share a similar space as
the ER in the cytoplasm, however, many other medium and small vacuoles as well as some other large
vacuoles were observed in the area not overlapping with the ER (Figure 6b). In addition, dextran
blue/yellow was added in the culture media during CX-4945 treatment to track the endocytosis
process. KKU-M213 engulfed dextran blue/yellow into the vacuoles, which showed as blue dots
of various sizes in the cytoplasm (Figure 6c). Dextran blue/yellow remained blue indicating that
pH of the vacuoles was neutral since it changes to green or yellow when the environment is acidic.
We conclude that the vacuoles formed from CX-4945 treatment did not alter nuclear and membrane
integrity. Furthermore, vacuoles in KKU-M213 are not formed from the ER, instead they are formed
from the endocytosis process as their pH is neutral. These finding meet the criteria for methuosis.
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clearly decreased in the 25 and 50 µM CX-4945 treated samples as well as in (b) HuCCA-1 and (f) 
KKU-M213 cell lines. (g) Percentage of dead cell increased in a dose-dependent manner in all three 
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Figure 4. CX-4945 induced cell death. Propidium iodide staining showed that treatment with CX-4945
for 4 h did not induce cell death in (a) HuCCA-1, (c) CCLP-1, and (e) KKU-M213 cells. Extended
CX-4945 treatment at 48 h, however, induced extensive cell death in (b) HuCCA-1 and (f) KKU-M213
cell lines. (d) Dead cell number was not increased in CCLP-1 treated with CX-4945 but live cell number
clearly decreased in the 25 and 50 µM CX-4945 treated samples as well as in (b) HuCCA-1 and (f)
KKU-M213 cell lines. (g) Percentage of dead cell increased in a dose-dependent manner in all three CCA
cell lines. ***; p < 0.001, Pictures are representative of the results from three independent experiments.
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Figure 5. CX-4945 induced non-apoptotic, non-autophagic cell death. (a) The apoptotic marker, 
cleaved caspase-3, and autophagic marker, LC3B-II, was not increased after 48 h of CX-4945 treatment 
when dead cells and vacuoles were observed. (b,c) The level of LC3B-II in HuCCA-1 and CCLP-1 cells 
increased at early time points, and then decreased after 3 h of 50 µM CX-4945 treatment in HuCCA-1 
cells and after 4 h in CCLP-1 cells. The level of LC3B-II in KKU-M213 decreased as soon as 15 min 
after 50 µM CX-4945 treatment. VC; vehicle control, *; p < 0.05, **; p < 0.01, ***; p < 0.001. All experiments 
were performed with at least three replicates. Graphs were plotted as mean ± SEM. 
2.7. CX-4945 Induced Vacuolization Is CK2-Independent 
To determine whether the effects of CX-4945 on vacuole formation were mediated by the 
inhibition of CK2, we next knocked down the expression of the α and α′ CK2 catalytic subunits using 
specific siRNAs (Figure 7a). Knockdown of both CK2 α and α′ in the HuCCA-1, CCLP-1, and KKU-
M213 CCA cell lines was verified using Western blotting (Figure 6a). In all three cell lines, knockdown 
of CK2 α and CK2 α′ decreased the levels of multiple phospho-CK2 substrates (Figure 7b). A 
reduction in phospho-CK2 substrate levels was observed for proteins with apparent molecular 
masses of 180, 110, 60, and 37 kDa as indicated by arrows in the Figure (Figure 7b). However, CK2 α 
and CK2 α′ knockdown failed to induce vacuolization in any of the CCA cell lines (Figure 7c). To 
confirm these results, we next treated CCA cell lines with 4,5,6,7-Tetrabromobenzotriazole (TBB), a 
well-characterized inhibitor of CK2 activity. Treatment with TBB did not induce the formation of 
vacuoles in any of the three CCA cells lines (Figure 7e–g) although it did block the phosphorylation 
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i re 5. CX-4945 induced no -apo totic, non-autophagic cell death. (a) The apoptotic marker, cleaved
caspase-3, and autoph gic marker, LC3B-II, was not increased after 48 h of CX-4945 treatment when
dead c lls and vacuoles w re observed. (b,c) The l v l of LC3B-II in HuCCA-1 a - lls
i cr s t rl ti e i ts, a t e ecrease after 3 h of 50 µ -4945 treat e t i -1
c ll 4 h in CCLP-1 cells. The level of LC3B-II in KKU-M213 decreas d as soon as 15 min after
50 µM CX-4945 treatment. VC; vehicle ontrol, *; p < 0.05, **; p < 0. 1, * ; p < 0.0 . i ts
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2.7. C -4945 Induced acuolization Is CK2-Independent
To determine whether the effects of CX-4945 on vacuole formation were mediated by the inhibition
of CK2, we next knocked down the expression of the α and α′ CK2 catalytic subunits using specific
siRNAs (Figure 7a). Knockdown of both CK2 α and α′ in the HuCCA-1, CCLP-1, and KKU-M213
CCA cell lines was verified using Western blotting (Figure 6a). In all three cell lines, knockdown of
CK2 α and CK2 α′ decreased the levels of multiple phospho-CK2 substrates (Figure 7b). A reduction
in phospho-CK2 substrate levels was observed for proteins with apparent molecular masses of 180,
110, 60, and 37 kDa as indicated by arrows in the Figure (Figure 7b). However, CK2 α and C 2 α′
knockdown failed to induce vacuolization in any of the CCA cell lines (Figure 7c). To confirm these
results, we next treated CCA cell lines with 4,5,6,7-Tetrabromobenzotriazole (TBB), a well-characterized
inhibitor of CK2 activity. Treatment with TBB did not induce the formation of vacuoles in any of
the three CCA cells lines (Figure 7e–g) although it did block the phosphorylation of multiple CK2
substrates in HuCCA-1 and KKU-M213 cell lines (Figure 7d). We conclude that the induction of
vacuoles by CX-4945, at least in HuCCA-1 and KKU-M213 cells, is not mediated by the inhibition of
CK2 activity.
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Figure 6. CX-4945 induced methuosis in CCA cell line, KKU-M213. (a) CX-4945 induced cytoplasmic
vacuolization in three CCA cell lines (HuCCA-1, CCLP-1, and KKU-M213) prostate cancer cell line
(DU145), and breast cancer cell line (MDA-MB-231), while it left the nucleus intact as compared to
the vehicle control group. (b) The endoplasmic reticulum (ER) of KKU-M213 showed no sign of
swelling during vacuolization induced by CX-4945. (c) The vacuoles induced by CX-4945 contained
dextran blue/yellow, which was added in the culture media during CX-4945 incubation. The presence
of dextran blue/yellow in the vacuoles indicated that cell engulfed extracellular fluid and formed
vacuoles. VC; vehicle control, arrow head indicates cytoplasmic vacuole.
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Figure 7. CK2 knockdown and inhibition of CK2 with 4,5,6,7-Tetrabromobenzotriazole (TBB) failed to
induce vacuolization. (a) Knockdown of α and α′ catalytic subunits of protein kinase CK2 using small
interfering (siRNA). (b) Knockdown of α and α′ catalytic subunits of protein kinase CK2 decreased
phospho-CK2 substrate levels in HuCCA-1, CCLP-1, and KKU-M213 cell lines. (c) Knockdown of α
and α′ catalytic subunits of protein kinase CK2 failed to induce cytoplasmic vacuolization. (d) TBB
reduced levels of phospho-CK2 substrate levels in HuCCA-1 and KKU-M213 cell lines. (e–g) TBB failed
to induce cytoplasmic vacuolization. WT; wild type, Scr; scramble siRNA. Pictures are representative
of the results from three independent experiments.
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2.8. CK2 Knockdown Inhibited CCA Cell Proliferation and Cell Invasion
To investigate the effects of CK2 α and CK2 α′ knockdown on CCA cell proliferation, we next
examined cell number and assayed BrdU incorporation. Combined CK2 α and CK2 α′ knockdown
had no effect on HUCCA-1 cell number over 5 days in culture and only a modest effect on the number
of CCLP-1 and KKU-M213 cells (Figure 8a). CCLP-1 and KKU-M213 cell number was decreased
by 25% at 5 days after gene knockdown. In contrast to the biphasic effects of CX-4945 treatment
on CCA cell invasion, combined CK2 α and CK2 α′ knockdown inhibited CCA cell invasion in
HuCCA-1 and KKU-M213 cells. HuCCA-1 cell invasion was inhibited to approximately 60% of the
control, while KKU-M213 cell invasion was inhibited to approximately 45% of the control (Figure 8b).
Moreover, CK2 α and CK2 α′ knockdown had no effect on invasion of CCLP-1 cells. We conclude
that the effects of CX-4945 treatment on CCA cell proliferation and cell invasion are unlikely to be
mediated by the inhibition of CK2 in these cells.
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and KKU-M213 cell number as determined using MTT assays. (b) Knockdown of α and α′ catalytic
subunits of protein kinase CK2 reduced HuCCA-1 and KKU-M213 cell invasion. T; wild type, Scr;
scramble siRNA, *; p < 0.05, **; p < 0.01, ***; p < 0.001. All experiments were performed as at least three
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3. Discussion
CX-4945 is in clinical phase I/II trials for cholangiocarcinoma (ClinicalTrials.gov identifier:
NCT02128282). Moreover, this drug has shown a therapeutic potential in several other types of
cancer [17,22,28,44–46]. Herein, CX-4945, at 10 µM and above, was shown to decrease protein
kinase CK2 activity when delivered to CCA cells and to inhibit CCA cell proliferation (Figure 1).
Unexpectedly, treatment with CX-4945 had biphasic effects on the ability of CCA cells to invade
Matrigel. At 10 µM, CX-4945 inhibited CCA cell invasion through a reduction of MMP-9 and
MMP-7 levels plus an inhibitory effect on cell proliferation. Interestingly, lower doses of CX-4945
(1 and 5 µM) increased the levels of MMP-9, MMP-7, and MMP-2 (Figure 1e,f). A biphasic effect
of CX-4945 on cell proliferation has been reported previously in s22Rv1 prostate cancer cells [25],
UM-SCC1 head and neck cancer cells [47], and A549 lung cancer cells [48]. CX-4945 at 0.5, 0.1,
and 0.01 µM slightly stimulated cell proliferation in the aforementioned cell lines, whereas higher
doses inhibited cell proliferation [25,47,48]. Knockdown of the α and α′ catalytic subunits of CK2
simultaneously also significantly reduced the phosphorylation of multiple CK2 substrates indicating
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that CK2 knockdown and CX-4945 treatment both inhibited CK2 activity. We measured CK2 activity
indirectly by using an antibody against the phospho-CK2 substrate (motif pS/pTDXE) to measure the
amount of phosphorylated CK2 substrates. This method is widely used in literature to measure kinase
activity, such as activity of the following kinases CK2 [16,49–52], AMPK [53–63], AMT/ATR [64–70],
PKA [71–79], and PKC [77,80–88]. Both CK2 knockdown and CX-4945 treatment inhibited the
proliferation of CCA cells. However, in contrast to the biphasic effects of CX-4945 on CCA cell
invasion, CK2 knockdown only inhibited CCA cell invasion. These data suggest that CX-4945 treatment
increases CCA cell invasion independently of CK2 inhibition. In addition, intensive vacuolization
and cell death was observed following CX-4945 treatment (Figures 2 and 3), but vacuolization was
absent following CK2α and CK2α′ knockdown (Figure 7c) and following treatment with another CK2
inhibitor (Figure 7e–g). This suggests that the induction of vacuole formation is also an off target effect
of CX-4945. Recently, an off target effect of CX-4945 was reported. CX-4945 was reported to inhibit the
Cdc2-like kinases (Clks) resulting in a suppression of phosphorylation of serine/arginine (S/R) rich
proteins in mammalian cells [31]. In addition, CX-4945 has been shown to affect alternative splicing of
a wide range of genes in a CK2-independent manner [31]. Inhibition of these or other kinases may be
responsible for increased cell invasion and/or increased vacuolization and cell death.
It has been reported that CX-4945 induces apoptosis via caspase-3 activity in lung cancer cells [17]
and in primary CCA tumor lines [28]. Autophagy was induced by CX-4945 in pancreatic and lung
cancer cell lines [45,89]. Surprisingly, we have shown that CX-4945-induced cell death in CCA cell lines
was not accompanied by caspase-3 cleavage and did not appear to involve autophagy (Figure 5a,b)
despite the involvement of intensive cytoplasmic vacuolization. This phenomenon was observed in
a range of cell lines including CCA cell lines, immortalized cholangiocyte cell lines, breast and prostate
cancer cell lines, and HEK293T cells. CX-4945-induced vacuoles originated from an engulfment of
extracellular fluid, not from the ER. (Figure 6b,c). Interestingly, non-canonical cell death involving
intensive cytoplasmic vacuolization is a hallmark of methuosis, oncosis, paratosis, and necroptosis [35].
We propose that the non-apoptotic, non-autophagic cell death mechanism induced by CX-4945 is not
oncosis, paraptosis, or necroptosis according to the following criteria. First, no membrane blebbing
was observed (Figure 3a). Second, chromatin condensation and nuclear fragmentation were absent
(Figure 6a). Third, the vacuoles originated from an engulfment of extracellular fluid, not from the ER
(Figure 6b,c) [35]. Furthermore, the vacuoles merged with others into large vacuoles (Figure 2) and
their pH remained neutral (Figure 6c). All of the aforementioned data fit the criteria of methuosis,
therefore, we propose that CX-4945 induces methuosis at least in the CCA cell line KKU-M213.
Interestingly, PC3 prostate cancer cells did not form vacuoles. This absence of the vacuoles in PC3
cells suggests a cell line specific response to CX-4945. It seems likely that CX-4945 activity and its effects
on cell death are cell-type specific, that is, dependent on, for example, whether tumor suppressors such
as TP53 are wild type or mutant in the cell line being tested. Further study on the PC3 cell line might
elucidate the molecular mechanism underlying the CX-4945-induced vacuolization and cell death
reported in this study. Further investigation of the molecular mechanisms underlying CX-4945-induced
vacuolization and cell death might lead to a better understanding of possible combinations of this
treatment with other current chemotherapeutic drugs to optimize treatment outcomes in patients.
4. Materials and Methods
4.1. Cell Culture
Two cholangiocarcinoma cell lines, KKU-M055 and KKU-M213, established as previously
described [90], were purchased from the Japanese Collection of Research Bioresources (JCRB) Cell
Bank (Osaka, Japan). These two cell lines were from a Thai patient with an Opisthorchis viverrini record.
The immortalized cholangiocytes cell line, MMNK-1, was also purchased from the JCRB Cell Bank.
Intraheptic cholangiocarcinoma cell lines, HuCCA-1 were established and kindly provided by Prof.
Stitaya Sirisinha [91]. HuCCA-1 was derived from a Thai patient whose serum was positive for the
Cancers 2018, 10, 283 15 of 22
O. viverrini antigen [91]. Prostate cancer cell lines, PC3 and DU145, were purchased from American
Type Culture Collection (ATCC) (Manassas, VA, USA). The immortalized human cholangiocytes cell
line, AKN-1, and cholangiocarcinoma cell lines, CCLP-1, were kindly provided by Dr. Simon Afford.
Breast cancer cell lines, MDA-MB-231, T47D, MCF7, and HEK293T, were purchased from ATCC
(Manassas, VA, USA). HuCCA-1 and PC3 cells were maintained in HAM’s F-12 medium (Hyclone,
Pittsburgh, PA, USA) supplemented with 10% fetal bovine serum (FBS) (Gibco, Grand Island, NY, USA),
while CCLP-1, KKU-M055, KKU-M213, MMNK-1, AKN-1, DU145, HEK293T, MDA-MB-231, T47D,
and MCF7 cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Hyclone,
Pittsburgh, PA, USA) supplemented with 10% FBS and 1% MEM non-essential amino acid (Gibco,
Grand Island, NY, USA). All media were supplemented with 1% Penicillin/Streptomycin (Gibco,
Grand Island, NY, USA). All cell lines were maintained at 37 ◦C with 5% CO2.
4.2. MTT Assay
Cells were plated in tissue culture treated 96-well plates. After overnight adhesion to the plate,
the treatment group was incubated with the indicated concentrations of CX-4945 (Santa Cruz Biotechnology,
Dallas, TX, USA) or 4,5,6,7-tetrabromo-2-azabenzimidazole, 4,5,6,7-Tetrabromobenzotriazole (TBB)
(Sigma Aldrich, St. Louis, MO, USA). Media were changed and new treatments were added on
day 2. On day 0, 2, and 5, MTT reagent (Fisher Scientific, Hampton, NH, USA) was added to the
final concentration of 0.5 mg/mL and incubated for 2.5 h at 37 ◦C. A half volume of stop solution
(10% Sodium dodecyl sulfate (SDS) in 50% dimethylformamide in dH2O) was added and mixed
thoroughly before reading the absorbance at 560 nm on a plate reader.
4.3. BrdU Incorporation Assay
Cells were plated in tissue culture treated 96-well plates. BrdU incorporation was assessed by
using a BrdU Cell Proliferation kit (ab126556, Abcam, Cambridge, MA, USA). Cells were treated with
CX-4945 for 24 h. During the last 6 h, cells were incubated in a working stock of BrdU. After incubation
with BrdU, media was removed and a fixative was added and the plates were incubated for 30 min
at 23 ◦C. Reaction cocktail was added according to the manufacturer’s protocol. The plate was read
with a spectrophotometer plate reader at an absorbance at 450 nm. The average no BrdU background
measurement was subtracted from all experimental measurements.
4.4. Cell Invasion Assay
Eight micrometer polycarbonate membrane transwell inserts (Corning costar, New York, NY,
USA) were coated with 50 µL of a 1:9 ratio of Matrigel™ (BD Biosciences, San Jose, CA, USA) to serum
free medium, that was allowed to congeal at 37 ◦C for 30 min. A total of 5 × 104 cells was added
to the top chamber of each well in serum free medium. The bottom well was filled with complete
medium. Treatment was added in both the transwell and the bottom well. Cells were incubated for
24 h at a 37 ◦C in a humidified incubator with 5% CO2. The chambers were swabbed to remove cells
and the Matrigel™ remaining on the top of the membrane. Cells on the underside of the membrane
were fixed in methanol for 5 min and stained with 0.5% (w/v) crystal violet in 12% glutaraldehyde in
water for 5 min. Following a brief distilled H2O wash, cells were counted using a Nikon Eclipse T2S
phase contrast inverted fluorescent microscope.
4.5. Cell Viability Assay
Cells were plated in tissue culture treated 6-well plates and incubated overnight. CX-4945 treatments
were added and incubated for either 4 h or 48 h. Calcein-acetoxymethyl (AM) (Fisher Scientific) and
propidium iodide (Fisher Scientific) were added 30 min before imaging at a final concentration of
0.125 µM and 1.5 µM, respectively. Images were taken with Nikon Eclipse T2S phase contrast inverted
fluorescent microscope. Live cells were stained with calcein and showed a green fluorescent signal
while dead cells were stained with Propidium iodine and showed a red fluorescent signal. Green and
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red fluorescence pixels were counted using Adobe Photoshop software. Average live and dead cells
sizes were measured using Adobe Photoshop software.
4.6. Western Blot Analysis
A total of 20 µg of protein was separated electrophoretically and transferred to nitrocellulose
membrane (GE, Boston, MA, USA) at room temperature. Membranes were blocked in a blocking
buffer (4% bovine serum albumin (BSA) w/v in Tris-buffered saline, 0.1% Tween 20 (TBST)), and then
incubated with primary antibodies overnight at 4 ◦C on a rocking shaker. All antibodies were
diluted in blocking buffer. All primary antibodies were monoclonal rabbit anti-human antibodies.
Primary antibodies included 1:1500 MMP-9 (2270, Cell Signaling Technology, Danvers, MA, USA),
1:1000 MMP-7 (ab5706, Abcam), 1:1500 MMP-2 (4022, Cell Signaling Technology), 1:1500 cleaved
caspase-3 (9664, Cell Signaling Technology), 1:1500 phospho-CK2 substrate (motif pS/pTDXE) (8738,
Cell Signaling Technology), 1:1500 LC3B (3868, Cell Signaling Technology), and 1:5000 β-actin (A2066,
Sigma Aldrich, St. Louis, MO, USA). Membranes were incubated for 75 min on a rocking shaker
at 23 ◦C with secondary antibodies. Secondary antibodies included 1:5000 goat anti-rabbit IgG
conjugated with horseradish peroxidase (7074, Cell Signaling Technology) or 1:5000 horse anti-mouse
immunoglobulin G (IgG) conjugated with horseradish peroxidase (7076, Cell Signaling Technology).
Signal was visualized by autoradiography using enhanced chemiluminescence (ECL) and a horseradish
peroxidase (HRP) chemiluminescent substrate (Millipore, Burlington, MA, USA), and exposed to
Hyperfilm (GE Healthcare, Boston, MA, USA). Bands intensity was analyzed using ImageJ software.
4.7. siRNA Transfection
Transfection was performed by adding 4 × 105 cells to 100 nM siRNA mixture in Optimem
medium (Fisher Scientific) in a total volume of 500 µL. siRNAs were commercially available from
Qaigen (CK2α SI02660504 and SI02660497, CK2α′ SI00605416 and SI00605409). The mixture of siRNA
and cells was plated into 6-well plates and incubated in a 37 ◦C humidified incubator with 5% CO2 for
4 h. Complete growth medium was then added and incubated for 2 days before cells were used in
further experiments.
4.8. Organelle Labeling and Imaging
Cells were plated in tissue culture treated 6-well plates and incubated overnight. CellLight™
ER-GFP and BacMam 2.0 (C10590, Fisher Scientific) were added to cells and incubated for 72 h at
50 particles per cell. LysoSensor™ Yellow/Blue DND-160 (L7545 Fisher Scientific) was added 15 min
before the treatment. Treatment (25 µM CX-4945) was added and incubated for 6 h. Fresh culture
media was changed prior to imaging. Live cells were imaged with a fluorescent invested microscope
with cell culture chamber module (Olympus) at the Olympus Imaging Center, Mahidol University.
Cells were plated on circle cover slides in tissue culture 24-well plates and incubated overnight.
Twenty-five micromolars of CX-4945 was added and incubated for 24 h. Cells were fixed in 3.7%
formaldehyde in Phosphate buffered saline (PBS) for 10 min, and then permeabilized in 0.1% Triton
X-100 in PBS for 2 min. After incubation, cells were incubated in 300 nM DAPI in PBS to stain the
nuclei. Fixed cells were imaged with a confocal microscope (Olympus) at the Olympus Imaging Center,
Mahidol University.
4.9. Statistical Analysis
Data were graphed as mean ± standard error of the mean (SEM) using Prism Graphpad software
(version 6.01, GraphPad Software, La Jolla, CA, USA). Statistical analyses were performed using
ANOVA with Dunnett’s test by using JMP software (version 10.0.0, SAS Institute Inc., Cary, NC, USA).
All experiments were performed in triplicate.
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5. Conclusions
Our data suggest that CX-4945 inhibits cell proliferation and induces methuosis via CK2-independent
pathways. A biphasic effect of CX-4945 on CCA cell invasion was, at least in part, due to an alteration
of MMP-2, MMP-7, and MMP-9.
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